Abingworth, a UK-based life sciences investor backed by Carlyle, is raising up to $1.5bn for clinical trials and royalty partnerships with pharmaceutical companies. Recent collaborations with Gilead Sciences and Teva demonstrate the fund’s focus on funding late-stage trials for promising drugs. Abingworth’s successful track record in phase-three trials, coupled with the current demand for new medicines, positions the fund as an attractive option for pharma companies seeking to maximize drug development opportunities.
Full Article
The Smartest Dividend Stocks to Buy With $2,000 Right Now
The energy industry is crucial for everyday life but can be unpredictable; however, some companies excel in providing consistent and increasing dividends to shareholders. Investors should consider leading firms in renewable energy, oil and natural gas, and pipelines as they are well-positioned to maintain their dividend growth. Explain It To Me Like I'm 5: Energy is what makes our cars go and our computers work, and some companies do a really good job of sharing...
Read more